| 1 |
32924987 | Identification of a novel CpG methylation signature to predict prognosis in lung squamous cell carcinoma. | 2021 |
1 |
| 2 |
33288882 | Selective inhibition of stemness through EGFR/FOXA2/SOX9 axis reduces pancreatic cancer metastasis. | 2021 Jan |
1 |
| 3 |
33432347 | Epidermal growth factor receptor promotes tumor progression and contributes to gemcitabine resistance in osteosarcoma. | 2021 Mar 2 |
5 |
| 4 |
33878513 | CUDC-101 enhances the chemosensitivity of gemcitabine-treated lymphoma cells. | 2021 Jul |
1 |
| 5 |
34061460 | Lung squamous cell carcinoma with severe hypomagnesemia due to cisplatin plus gemcitabine in combination with necitumumab therapy: A case report. | 2021 Jul |
2 |
| 6 |
34123574 | Priming of pancreatic cancer cells with bispecific antibody armed activated T cells sensitizes tumors for enhanced chemoresponsiveness. | 2021 Jun 1 |
1 |
| 7 |
34238922 | Exosomal annexin A6 induces gemcitabine resistance by inhibiting ubiquitination and degradation of EGFR in triple-negative breast cancer. | 2021 Jul 8 |
3 |
| 8 |
34805140 | Effect of Photodynamic Therapy on Gemcitabine-Resistant Cholangiocarcinoma in vitro and in vivo Through KLF10 and EGFR. | 2021 |
3 |
| 9 |
32111094 | Local Delivery of Gemcitabine Inhibits Pancreatic and Cholangiocarcinoma Tumor Growth by Promoting Epidermal Growth Factor Receptor Degradation. | 2020 Feb 26 |
2 |
| 10 |
32111744 | Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis. | 2020 Mar-Apr |
1 |
| 11 |
32235891 | Hexosamine pathway inhibition overcomes pancreatic cancer resistance to gemcitabine through unfolded protein response and EGFR-Akt pathway modulation. | 2020 May |
1 |
| 12 |
32622356 | Gallbladder cancer with EGFR mutation and its response to GemOx with erlotinib: a case report and review of literature. | 2020 Jul 4 |
1 |
| 13 |
30679315 | A Phase II Randomized Trial of Panitumumab, Erlotinib, and Gemcitabine Versus Erlotinib and Gemcitabine in Patients with Untreated, Metastatic Pancreatic Adenocarcinoma: North Central Cancer Treatment Group Trial N064B (Alliance). | 2019 May |
3 |
| 14 |
31289485 | Positive PD-L1 expression is predictive for patients with advanced EGFR wild-type non-small cell lung cancer treated with gemcitabine and cisplatin. | 2019 Jul |
1 |
| 15 |
31387179 | Enhancement of chemosensitivity by WEE1 inhibition in EGFR-TKIs resistant non-small cell lung cancer. | 2019 Sep |
2 |
| 16 |
31550632 | Electrochemical molecularly bioimprinted siloxane biosensor on the basis of core/shell silver nanoparticles/EGFR exon 21 L858R point mutant gene/siloxane film for ultra-sensing of Gemcitabine as a lung cancer chemotherapy medication. | 2019 Dec 1 |
3 |
| 17 |
29141539 | Selectively Targeted Anti-Neoplastic Cytotoxicity of Three Immunopharmaceuticals with Covalently Bound Fludarabine, Gemcitabine and Dexamethasone Moieties Synthesized Utilizing Organic Chemistry Reactions in a Multi-Stage Regimen. | 2018 |
1 |
| 18 |
29352306 | Prognostic and predictive role of EGFR pathway alterations in biliary cancer patients treated with chemotherapy and anti-EGFR. | 2018 |
1 |
| 19 |
29851753 | Downregulation of GEP100 Improved the Growth Inhibition Effect of Erlotinib Through Modulating Mesenchymal Epithelial Transition Process in Pancreatic Cancer. | 2018 Jul |
1 |
| 20 |
30407790 | Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation. | 2018 Nov 27 |
3 |
| 21 |
28719220 | EGFR-Targeted Cationic Polymeric Mixed Micelles for Codelivery of Gemcitabine and miR-205 for Treating Advanced Pancreatic Cancer. | 2017 Sep 5 |
1 |
| 22 |
28927112 | Non-small cell lung cancer PC-9 cells exhibit increased sensitivity to gemcitabine and vinorelbine upon acquiring resistance to EGFR-tyrosine kinase inhibitors. | 2017 Sep |
4 |
| 23 |
28938567 | Gemcitabine-induced heparanase promotes aggressiveness of pancreatic cancer cells via activating EGFR signaling. | 2017 Aug 29 |
2 |
| 24 |
26626700 | EGFR-Targeted Polymeric Mixed Micelles Carrying Gemcitabine for Treating Pancreatic Cancer. | 2016 Jan 11 |
1 |
| 25 |
26650486 | The relationship between RRM1 gene polymorphisms and effectiveness of gemcitabine-based first-line chemotherapy in advanced NSCLC patient. | 2016 Sep |
1 |
| 26 |
26656632 | EGFR-targeted gelatin nanoparticles for systemic administration of gemcitabine in an orthotopic pancreatic cancer model. | 2016 Apr |
6 |
| 27 |
27070783 | Expression and Prognostic Significance of Human Epidermal Growth Factor Receptors 1, 2 and 3 in Periampullary Adenocarcinoma. | 2016 |
1 |
| 28 |
27101576 | miR-216b Targets FGFR1 and Confers Sensitivity to Radiotherapy in Pancreatic Ductal Adenocarcinoma Patients Without EGFR or KRAS Mutation. | 2016 Oct |
1 |
| 29 |
27556697 | Gemcitabine enhances cell invasion via activating HAb18G/CD147-EGFR-pSTAT3 signaling. | 2016 Sep 20 |
4 |
| 30 |
32263194 | Development of gelatin nanoparticles conjugated with phytohemagglutinin erythroagglutinating loaded with gemcitabine for inducing apoptosis in non-small cell lung cancer cells. | 2016 Apr 14 |
1 |
| 31 |
25550550 | KML001 enhances anticancer activity of gemcitabine against pancreatic cancer cells. | 2015 Jan |
1 |
| 32 |
25776490 | Molecularly targeted gemcitabine-loaded nanoparticulate system towards the treatment of EGFR overexpressing lung cancer. | 2015 Mar |
3 |
| 33 |
25821636 | Simultaneous Dual Selective Targeted Delivery of Two Covalent Gemcitabine Immunochemotherapeutics and Complementary Anti-Neoplastic Potency of [Se]-Methylselenocysteine. | 2015 Jan |
6 |
| 34 |
26046796 | Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. | 2015 Jul 20 |
1 |
| 35 |
26056353 | Phase I Clinical Trial to Determine the Feasibility and Maximum Tolerated Dose of Panitumumab to Standard Gemcitabine-Based Chemoradiation in Locally Advanced Pancreatic Cancer. | 2015 Oct 15 |
2 |
| 36 |
24142531 | Efficacy of nimotuzumab plus gemcitabine usage as first-line treatment in patients with advanced pancreatic cancer. | 2014 Mar |
1 |
| 37 |
24838526 | Gemcitabine and CHK1 inhibition potentiate EGFR-directed radioimmunotherapy against pancreatic ductal adenocarcinoma. | 2014 Jun 15 |
1 |
| 38 |
25041791 | Dual blockade of epidermal growth factor receptor and insulin-like growth factor receptor-1 signaling in metastatic pancreatic cancer: phase Ib and randomized phase II trial of gemcitabine, erlotinib, and cixutumumab versus gemcitabine plus erlotinib (SWOG S0727). | 2014 Oct 1 |
2 |
| 39 |
25844392 | Anti-Neoplastic Cytotoxicity of Gemcitabine-(C4-amide)-[anti-EGFR] in Dual-combination with Epirubicin-(C3-amide)-[anti-HER2/neu] against Chemotherapeutic-Resistant Mammary Adenocarcinoma (SKBr-3) and the Complementary Effect of Mebendazole. | 2014 Apr 9 |
4 |
| 40 |
23255896 | Sorafenib combined with gemcitabine in EGFR-TKI-resistant human lung cancer cells. | 2013 Jan |
2 |
| 41 |
23420122 | Synergistic interaction between sorafenib and gemcitabine in EGFR-TKI-sensitive and EGFR-TKI-resistant human lung cancer cell lines. | 2013 Feb |
4 |
| 42 |
23456778 | Quality of life (QoL) analyses from OPTIMAL (CTONG-0802), a phase III, randomised, open-label study of first-line erlotinib versus chemotherapy in patients with advanced EGFR mutation-positive non-small-cell lung cancer (NSCLC). | 2013 Jun |
1 |
| 43 |
23890141 | Efficacy and safety profile of combining agents against epidermal growth factor receptor or vascular endothelium growth factor receptor with gemcitabine-based chemotherapy in patients with advanced pancreatic cancer: a meta-analysis. | 2013 Jul-Aug |
3 |
| 44 |
23910066 | Response to first-line chemotherapy in patients with non-small-cell lung cancer according to epidermal growth factor receptor and K-RAS mutation status. | 2013 Nov |
3 |
| 45 |
24025152 | Inhibiting signal transducer and activator of transcription-3 increases response to gemcitabine and delays progression of pancreatic cancer. | 2013 Sep 11 |
1 |
| 46 |
22186617 | Genomics and pharmacogenomics of pancreatic adenocarcinoma. | 2012 Feb |
1 |
| 47 |
22521649 | EGFR mutations as a predictive marker of cytotoxic chemotherapy. | 2012 Aug |
2 |
| 48 |
23030589 | Aptamer-mediated delivery of chemotherapy to pancreatic cancer cells. | 2012 Oct |
2 |
| 49 |
20705357 | First-line therapy and methylation status of CHFR in serum influence outcome to chemotherapy versus EGFR tyrosine kinase inhibitors as second-line therapy in stage IV non-small-cell lung cancer patients. | 2011 Apr |
1 |
| 50 |
21080748 | Erlotinib resistance is altered after gemcitabine chemotherapy for recurrent non-small-cell lung cancer. | 2011 |
2 |